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Abstract
Introduction: Alport syndrome is a rare genetic disorder that 
affects as many as 60,000 persons in the USA and a total of 
103,000 persons (<5 per 10,000) in the European Union [1, 2]. 
It is the second most common inherited cause of kidney fail-
ure and is characterized by progressive loss of kidney func-
tion that often leads to end-stage kidney disease. Currently, 
there are no approved disease-specific agents for therapeu-
tic use. We designed a phase 3 study (CARDINAL; 
NCT03019185) to evaluate the safety, tolerability, and effi-
cacy of bardoxolone methyl in patients with Alport syn-
drome. Methods: The CARDINAL phase 3 study is an interna-
tional, multicenter, double-blind, placebo-controlled, ran-
domized registrational trial. Eligible patients were of ages 
12–70 years with confirmed genetic or histologic diagnosis 
of Alport syndrome, eGFR 30–90 mL/min/1.73 m2, and uri-
nary albumin to creatinine ratio (UACR) ≤3,500 mg/g. Pa-
tients with B-type natriuretic peptide values >200 pg/mL at 
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baseline or with significant cardiovascular histories were ex-
cluded. Patients were randomized 1:1 to bardoxolone meth-
yl or placebo, with stratification by baseline UACR. Results: 
A total of 371 patients were screened, and 157 patients were 
randomly assigned to receive bardoxolone methyl (n = 77) 
or placebo (n = 80). The average age at screening was 39.2 
years, and 23 (15%) were <18 years of age. Of the random-
ized population, 146 (93%) had confirmed genetic diagnosis 
of Alport syndrome, and 62% of patients had X-linked mode 
of inheritance. Mean baseline eGFR was 62.7 mL/min/1.73 
m2, and the geometric mean UACR was 141.0 mg/g. The av-
erage annual rate of eGFR decline prior to enrollment in the 
study was −4.9 mL/min/1.73 m2 despite 78% of the patient 
population receiving ACE inhibitor (ACEi) or ARB therapy. 
Discussion/Conclusion: CARDINAL is one of the largest in-
terventional, randomized controlled trials in Alport syn-
drome conducted to date. Despite the use of ACEi or ARB, 
patients were experiencing significant loss of kidney func-
tion prior to study entry. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Alport syndrome is a rare and serious genetic disease 
that affects as many as 60,000 persons in the USA and an 
estimated 103,000 persons (<5 per 10,000) in the Euro-
pean Union [1, 2]. It is the second most common inher-
ited cause of kidney failure after polycystic kidney disease 
[3]. Alport syndrome is caused by mutations in the 
 COL4A3, COL4A4, and COL4A5 genes, encoding the α3, 
α4, and α5 chains of type IV collagen. Type IV collagen is 
a major constituent of basement membranes. More than 
500 different mutations have been described, mostly 
linked to X-linked chromosomal (XLAS, 67%) and auto-
somal dominant inheritance [4]. The defective type IV 
collagen in Alport syndrome leads to typical splitting in 
the glomerular basement membrane, podocyte efface-
ment, glomerulosclerosis with matrix deposition, and 
kidney fibrosis and end-stage kidney disease (ESKD) ear-
ly in life. Although the genetic defect affects type IV col-
lagen in the glomerular basement membrane, secondary 
events lead to tubulointerstitial fibrosis with resulting loss 
of kidney function [5].
Current treatment recommendations [6, 7] include 
drugs that block the renin-angiotensin aldosterone sys-
tem in proteinuric patients with Alport syndrome. While 
these agents consistently reduce blood pressure and pro-
teinuria across a broad range of glomerular diseases, the 
effects of renin-angiotensin aldosterone system inhibi-
tors in Alport syndrome have not been previously tested 
in any randomized controlled trial.
Bardoxolone methyl is a semisynthetic triterpenoid 
that activates nuclear factor erythroid 2-related factor 2 
(Nrf2), a transcription factor that modulates the expres-
sion of hundreds of genes involved in inflammation, oxi-
dative stress, and cellular energy metabolism [8, 9]. By 
activating the Keap1-Nrf2 pathway, bardoxolone methyl 
also suppresses nuclear factor kappa-light-chain-enhanc-
er of activated B cells (NF-κB), the primary transcription 
factor producing proteins that mediate inflammation and 
the production of reactive oxygen species [10–15]. Bar-
doxolone methyl has been studied in multiple clinical tri-
als that together have enrolled >3,000 patients with one 
of six different forms of CKD, including Alport syn-
drome, autosomal dominant polycystic kidney disease 
(ADPKD), IgA nephropathy, focal segmental glomerulo-
sclerosis (FSGS), and diabetic kidney disease. In these 
clinical studies, treatment with bardoxolone methyl has 
consistently improved kidney function as assessed by ei-
ther inulin clearance, creatinine clearance, or estimated 
GFR (eGFR) [16–18]. Increases in eGFR with bardoxo-
lone methyl treatment relative to placebo have been ob-
served in multiple long-term clinical studies, which per-
sist approximately 4 weeks after cessation of the drug [16, 
17, 19]. These results are thought to reflect the drug’s an-
tifibrotic effects and are consistent with beneficial effects 
on structural remodeling observed in animal models of 
CKD [20–24]. In patients with Alport syndrome, the sus-
tained improvement in kidney function could provide a 
multi-year delay in disease progression to ESKD.
Materials and Methods
Overview
CARDINAL (NCT03019185) is an international, multicenter, 
phase 2/3 trial designed to assess the safety, tolerability, and effi-
cacy of bardoxolone methyl in qualified patients with Alport syn-
drome. The CARDINAL phase 2 study was open label and enrolled 
30 patients, and it is not the subject of this publication. The CAR-
DINAL phase 3 study is an international, double-blind, random-
ized, placebo-controlled trial. The general design and participants’ 
baseline characteristics from the CARDINAL phase 3 study are 
discussed herein.
Patient Population
We enrolled patients aged 12–70 years with Alport syndrome 
diagnosed histologically (by electron microscopy) or genetically by 
a documented mutation in disease-associated genes, including 
COL4A3, COL4A4, or COL4A5. Genetic testing was conducted as 
part of the trial by an independent vendor (Machaon Diagnostics, 
Oakland, CA, USA) unless patients provided documentation of 
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prior genetic or histological diagnosis for eligibility. Patients had 
eGFR between 30 and 90 mL/min/1.73 m2 (inclusive) and urinary 
albumin to creatinine ratio (UACR) ≤3,500 mg/g. Patients with 
macroalbuminuria (UACR of 301–3,500 mg/g) were to comprise 
no >40% of enrolled trial participants. Patients were to have re-
ceived maximally tolerated labeled doses of an angiotensin-con-
verting enzyme inhibitor (ACEi) and/or angiotensin receptor 
blocker (ARB), unless medically contraindicated. Patients with 
clinically significant cardiovascular disease or serum B-type natri-
uretic peptide concentrations >200 pg/mL during screening were 
not eligible for the study. Patients with uncontrolled diabetes and/
or hypertension were also excluded.
Study Outcomes
The primary efficacy endpoint for CARDINAL is change from 
baseline in eGFR in bardoxolone methyl-treated patients relative 
to placebo after 48 and 100 weeks of treatment. Key secondary 
endpoints were the off-treatment changes from baseline in eGFR 
at weeks 52 and 104, following a 4-week withdrawal period.
Several exploratory endpoints at the 48- and 100-week time 
points will also be considered: (1) the proportion of patients who 
experienced either a 30% increase or decrease from baseline in 
eGFR; (2) the distribution of changes in eGFR from baseline; (3) 
Patient Global Impression of Change (PGIC) and Clinical Global 
Impression-Improvement (CGI-I) scores after 48 and 100 weeks 
of treatment; and (4) the proportion of patients with a kidney fail-
ure event defined as the composite endpoint consisting of con-
firmed ≥30% decline from baseline in eGFR, confirmed eGFR <15 
mL/min/1.73 m2, or ESKD (initiation of maintenance dialysis or 
kidney transplant).
Study Design
Patients with Alport syndrome who met the inclusion and ex-
clusion criteria were randomized 1:1 to receive either bardoxolone 
methyl or placebo. Randomization was stratified by baseline 
UACR (≤300 mg/g, 300 to ≤1,000 mg/g, and 1,000 to ≤3,500 mg/g). 
Patients randomized to placebo remained on placebo throughout 
the study, undergoing sham dose titration. The target maximum 
bardoxolone methyl dose was determined by baseline proteinuria 
status. Adult patients started once-daily dosing by receiving 5 mg 
for the first week, and dose escalated to 10 mg at week 2, to 20 mg 
at week 4, and lastly to 30 mg at week 6 (only if baseline UACR 
>300 mg/g). Patients <18 years of age started bardoxolone methyl 
dosing at 5 mg every other day for the first week, followed by 5 mg 
once daily at week 2, and then increased dosage every 2 weeks fol-
lowing the same aforementioned dose-titration scheme based on 
baseline UACR at weeks 2, 4, and 6 to achieve the same target 
doses as adult patients.
All patients in the study follow the same visit and assessment 
schedule (Fig. 1). Following randomization on day 1, patients are 
assessed in-person at weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 
88, 100, and 104 and by telephone contact on days 3, 10, 21, 31, 38, 
and 45. Study drug is discontinued for 4 weeks between weeks 48 
and 52. Patients restart treatment at week 52 at the same dose re-
ceived at week 48, and patients continue study drug treatment 
through week 100. At week 100 visit study, the drug was discon-
tinued again for 4 weeks, and a follow-up visit is scheduled at week 
104.
We calculated eGFR using the Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI) equation or Bedside Schwartz 
equation for patients under the age of 18 at the time of consent. 
Pediatric patients who turned 18 during the conduct of the trial 
continued to have eGFR calculated with the Bedside Schwartz 
equation. Clinical lab evaluations, including eGFR, were assessed 
at each in-person visit. We collected historical eGFR data from all 
patients for a period of up to 5 years prior to study entry to estimate 
the annualized change in eGFR. We converted all historical serum 
creatinine values to mg/dL in order to calculate eGFR according to 
the appropriate equation using the patient age at laboratory collec-
tion for adult patients, or patient height at screening for pediatric 
patients. Historical serum creatinine and corresponding eGFR val-
ues were considered part of a patient’s medical history and distinct 
from central lab assessments collected as part of the trial. We col-
lected first morning void urine samples for UACR at screening and 
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Fig. 1. CARDINAL trial design. UACR, urinary albumin to creatinine ratio; Bard, bardoxolone methyl; eGFR, 
estimated glomerular filtration rate; F/U, follow-up; ScrA, screening visit A; ScrB, screening visit B; W/D, with-
drawal.
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every 4 weeks until week 12 and every 12 weeks thereafter until the 
end of treatment; UACR was also assessed at weeks 52 and 104 fol-
lowing a 4-week study drug withdrawal period. We conducted 
pure tone audiology tests at day 1 and weeks 48 and 100 to assess 
changes in hearing, also an exploratory outcome.
Statistical Analysis
We summarize demographics and baseline clinical character-
istics using descriptive statistics; continuous data are summarized 
with number of mean or geometric mean (where noted) and stan-
dard deviation (SD). Categorical data are summarized using pro-
portions.
We defined baseline eGFR for the study as the average of the 2 
screening measurements and the day 1 eGFR measurement. For 
evaluation of the eGFR trajectory before trial participation, we ob-
tained all eGFR values before trial participation going as far back 
as the eGFR value closest to 5 years but not >5.5 years and calcu-
lated the annualized eGFR slope (in mL/min/1.73 m2/year). We 
employed a longitudinal mixed model with the eGFR at each avail-
able time point as the dependent variable and time in years as the 
covariate. UACR results were log transformed for analysis and 
summarized using geometric means. In accordance with pub-
lished guidance, we did not perform inference tests comparing 
baseline characteristics across groups.
Results
Enrollment
Between August 2017 and November 2018, 371 pa-
tients were screened, and of those 157 enrolled at 47 study 
sites in the USA, Europe, Japan, and Australia. Patients 
were randomly allocated to bardoxolone methyl (77 pa-
tients) or placebo (80 patients). Main reasons for exclu-
sion were screening eGFR values that were <30 or >90 
mL/min/1.73 m2, UACR values >3,500 mg/g, and absence 
of genetic or histological confirmation of Alport syn-
drome diagnosis.
Demographic and Baseline Characteristics in the 
Overall, Adult, and Pediatric Populations
Baseline characteristics of the enrolled patient popula-
tion are shown in Table 1. The mean age was 39.2 years 
(range, 13–70 years), and 134 of 157 patients (85.0%) 
were 18 years or older. The majority of patients were fe-
male (91/157, 58%) and Caucasian (118/157, 75%).
The mean age at Alport syndrome diagnosis was 29.7 
years for the overall population. Of the enrolled patients, 
32 (20%) had a histological diagnosis and 146 (93%) had 
a genetic diagnosis of Alport syndrome; 98 (62%) had an 
X-linked genetic subtype and 48 (31%) patients had a 
non-X-linked (autosomal recessive or dominant) genetic 
subtype. Most of the patients were receiving an ACEi or 
ARB (122 [78%]). Seventy (45%) patients reported im-
paired auditory acuity at the time of screening, and 135 
(86%) patients reported hematuria at baseline, which was 
not systematically assessed during the study. Mean weight 
and BMI were 75.0 kg and 26.6 kg/m2 at baseline, respec-
tively. Blood pressure was well controlled, with mean sys-
tolic and diastolic blood pressures of 120 and 73 mm Hg.
The mean ± SD baseline eGFR for the overall popula-
tion was 62.7 ± 17.9 mL/min/1.73 m2 with a total of 66 
(42%) patients having an eGFR value ≤60 mL/min/1.73 
m2. The average rate of annual eGFR decline prior to en-
rollment in the study was −4.9 mL/min/1.73 m2. The geo-
metric mean UACR at baseline for the overall patient 
population was 141.0 mg/g with 72 (46%) patients having 
an UACR >300 mg/g.
A total of 23 (15%) pediatric patients (<18 years of age) 
were randomized in the trial. The average age at screening 
for patients in the pediatric population was 15.3 ± 1.4 
years. A total of 14 of 23 (61%) patients in the pediatric 
population had an X-linked mode of inheritance, and 4 
(17%) patients were female. The pediatric population had 
a mean baseline eGFR value of 69.9 mL/min/1.73 m2. 
Thus, despite their young age, the enrolled pediatric pa-
tients had lost a meaningful degree of kidney function pri-
or to study entry. Moreover, the historical average annual 
eGFR decrease in these patients was −10.7 mL/min/1.73 
m2, a more rapid rate of disease progression than that ob-
served in the adult patients (−4.3 mL/min/1.73 m2 per 
year). The pediatric population had a higher baseline 
UACR than the adult population, with a mean baseline 
UACR of 230.9 mg/g, and 13 (57%) patients had UACR 
>300 mg/g. Eleven (48%) pediatric patients reported im-
paired auditory acuity at the time of the screening. Mean 
weight and BMI were slightly lower than the adult popula-
tion (61.1 kg and 21.1 kg/m2 at baseline, respectively).
Baseline Characteristics according to eGFR and 
Albuminuria Categories
Of the randomized patients, a total of 66 (42%) pa-
tients had baseline eGFR ≤60 mL/min/1.73 m2 (Table 2). 
Patients with a lower eGFR had a higher average UACR 
(268.8 mg/g), were older, and were more likely to be treat-
ed with ACEi or ARBs (60 [91%] patients) and to have 
X-linked Alport syndrome (44 [67%] compared to 54 
[59%] in the group with higher eGFR). Patients in this 
subgroup also had numerically higher mean systolic 
blood pressure compared to the patients with higher 
eGFR (124 vs. 117 mm Hg, respectively). Patients in the 
lower eGFR group were more likely to have had hearing 
loss at baseline (34 [52%] patients) than patients in the 
higher eGFR group (36 [40%] patients).
Chertow et al.Am J Nephrol 2021;52:180–189184
DOI: 10.1159/000513777
Seventy-two (46%) patients had a baseline UACR 
>300 mg/g (macroalbuminuria). Compared with patients 
with UACR ≤300 mg/g, patients with macroalbuminuria 
were younger and were diagnosed with Alport syndrome 
at a younger age, had a lower mean baseline eGFR (56.1 
mL/min/1.73 m2), and were more likely to be on ACEi or 
ARB (68 [94%] patients). Patients with macroalbumin-
uria were also more likely to be male (45 [63%] patients 
Table 1. Baseline characteristics
Parameter All Adult Pediatric
Patients, n 157 134 23
Age, years, mean ± SD 39.2±15.3 43.3±12.5 15.3±1.4
Age <18, n (%) 23 (15) 0 23 (100)
Sex (female), n (%) 91 (58) 87 (65) 4 (17)
Race, n (%)
White (Caucasian) 118 (75) 109 (81) 9 (39)
Asian 26 (17) 19 (14) 7 (30)
Black or African American 5 (3) 2 (2) 3 (13)
Others 8 (5) 4 (3) 4 (17)
Systolic blood pressure, mm Hg, mean ± SD 119.7±12.5 120.6±12.5 114.1±11.4
Diastolic blood pressure, mm Hg, mean ± SD 73.2±10.0 74.6±9.7 65.2±8.0
Baseline eGFR, mL/min/1.73 m2, mean ± SD 62.7±17.9 61.4±18.1 69.9±15.4
≤60 mL/min/1.73 m2, n (%) 66 (42) 62 (46) 4 (17)
>60 mL/min/1.73 m2, n (%) 91 (58) 72 (54) 19 (83)
Historic annual change in eGFR, mL/min/1.73 m2, mean ± SE −4.85±0.38 −4.28±0.39 −10.74±1.19
ACR, mg/g, geometric mean ± SE 141.0±23.9 129.5±23.9 230.9±95.8
<30 mg/g, n (%) 39 (25) 36 (27) 3 (13)
≤300 mg/g 85 (54) 75 (56) 10 (44)
>300 mg/g 72 (46) 59 (44) 13 (57)
>1,000 mg/g 36 (23) 28 (21) 8 (35)
Baseline CKD stage, n (%)
1 3 (2) 3 (2) 0
2 89 (57) 70 (52) 19 (83)
3a 33 (21) 32 (24) 1 (4)
3b 29 (19) 26 (19) 3 (13)
4 3 (2) 3 (2) 0
Age at Alport syndrome diagnosis, years, mean ± SD 29.7±17.9 33.0±17.2 10.5±5.1
Confirmed histologic diagnosis of Alport syndrome, n (%) 32 (20) 26 (19) 6 (26)
Confirmed genetic diagnosis of Alport syndrome, n (%) 146 (93) 126 (94) 20 (87)
Mode of inheritance, n (%)
X-linked 98 (62) 84 (63) 14 (61)
Autosomal (recessive or dominant) 48 (31) 42 (31) 6 (26)
Genotype, n (%)
COL4A3 mutation 14 (9) 12 (9) 2 (9)
COL4A4 mutation 30 (19) 27 (20) 3 (13)
COL4A3 and COL4A4 mutation 4 (3) 3 (2) 1 (4)
COL4A5 mutation 98 (62) 84 (63) 14 (61)
COL4A3 and COL4A5 mutation 1 (1) 1 (1) 0
COL4A4 and COL4A5 mutation 1 (1) 1 (1) 0
ACEi/ARB treatment, n (%) 122 (78) 105 (78) 17 (74)
Hearing loss, n (%) 70 (45) 59 (44) 11 (48)
Hematuria, n (%) 135 (86) 116 (87) 19 (83)
Weight, kg, mean ± SD 75.0±18.0 77.4±17.7 61.1±13.7
Body mass index, kg/m2, mean ± SD 26.6±5.9 27.5±5.8 21.1±3.0
eGFR, estimated glomerular filtration rate; UACR, urinary albumin to creatinine ratio; ACEi, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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compared to 66 [42%] patients in the overall patient pop-
ulation and 21 [25%] patients in the subgroup with lower 
UACR) and more likely to have X-linked Alport syn-
drome (49 [68%] patients compared to 49 [58%] in the 
subgroup with lower UACR). These patients had a nu-
merically higher mean systolic blood pressure compared 
to the patients with lower UACR (124 vs. 116 mm Hg, 
respectively) and were also more likely to have had hear-
ing loss (40 [56%] patients vs. 30 [35%] patients, respec-
tively).
Discussion
The CARDINAL trial is a multinational randomized 
double-blind, placebo-controlled trial evaluating the 
safety and efficacy of bardoxolone methyl in patients with 
Alport syndrome. A key secondary endpoint of the trial 
is the off-treatment change from baseline at week 52 (af-
ter 48 weeks of treatment) and again at week 104 after the 
second year of treatment. The off-treatment endpoint fol-
lows recent recommendations by the NKF-FDA-EMA 
Table 2. Baseline characteristics according to eGFR and albuminuria categories
Parameter Baseline eGFR Baseline ACR
≤60 mL/min/1.73 m2 >60 mL/min/1.73 m2 ≤300 mg/g >300 mg/g
Patients, n 66 91 85 72
Age, years, mean ± SD 44.5±14.9 35.4±14.4 43.3±14.4 34.4±15.0
Age <18, n (%) 4 (6) 19 (21) 10 (12) 13 (18)
Sex (female), n (%) 37 (56) 54 (59) 64 (75) 27 (38)
Race, n (%)
White (Caucasian) 55 (83) 63 (69) 72 (85) 46 (64)
Black or African American 1 (2) 4 (4) 4 (5) 1 (1)
Asian 7 (11) 19 (21) 8 (9) 18 (25)
Others 3 (5) 5 (6) 1 (1) 7 (10)
Systolic blood pressure, mm Hg, mean ± SD 123.5±12.9 116.9±11.5 116.4±11.5 123.5±12.7
Diastolic blood pressure, mm Hg, mean ± SD 76.5±9.8 70.8±9.5 71.3±9.0 75.4±10.7
Baseline eGFR, mL/min/1.73 m2, mean ± SD 44.5±9.6 75.9±8.3 68.3±16.6 56.1±17.3
≤60 mL/min/1.73 m2, n (%) 66 (100) 0 28 (33) 38 (53)
>60 mL/min/1.73 m2, n (%) 0 91 (100) 57 (67) 34 (47)
ACR, mg/g, geometric mean ± SE 268.8±66.7 88.3±19.3 28.3±4.7 938.0±69.7
<30 mg/g, n (%) 9 (14) 30 (33) 39 (46) 0
30 to ≤300 mg/g, n (%) 28 (42) 57 (63) 85 (100) 0
>300 to ≤1,000 mg/g, n (%) 38 (58) 34 (38) 0 72 (100)
>1,000 mg/g, n (%) 25 (38) 11 (12) 0 36 (50)
Age at Alport syndrome diagnosis, years, mean ± SD 32.2±19.7 27.8±16.3 34.4±17.4 24.1±16.9
Confirmed histologic diagnosis of Alport syndrome, n (%) 17 (26) 15 (17) 12 (14) 20 (28)
Confirmed genetic diagnosis of Alport syndrome, n (%) 61 (92) 85 (93) 82 (96) 64 (89)
Mode of inheritance, n (%)
X-linked 44 (67) 54 (59) 49 (58) 49 (68)
Autosomal (recessive or dominant) 17 (26) 31 (34) 33 (39) 15 (21)
Genotype, n (%)
COL4A3 mutation 4 (6) 10 (11) 8 (9) 6 (8)
COL4A4 mutation 12 (18) 18 (20) 22 (26) 8 (11)
COL4A3 and COL4A4 mutation 1 (2) 3 (3) 3 (4) 1 (1)
COL4A5 mutation 44 (67) 54 (59) 49 (58) 49 (68)
COL4A3 and COL4A5 mutation 1 (2) 0 0 1 (1)
COL4A4 and COL4A5 mutation 0 1 (1) 1 (1) 0
ACEi/ARB treatment, n (%) 60 (91) 62 (68) 54 (64) 68 (94)
Hearing loss, n (%) 34 (52) 36 (40) 30 (35) 40 (56)
Hematuria, n (%) 54 (82) 81 (89) 73 (86) 62 (86)
eGFR, estimated glomerular filtration rate; UACR, urinary albumin to creatinine ratio; ACEi, angiotensin-converting enzyme 
inhibitor; ARB, angiotensin receptor blocker.
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Scientific Working group for evaluating off-treatment 
changes in eGFR cases where acute eGFR effects are ob-
served [25] and will evaluate bardoxolone methyl’s effect 
on the loss of kidney function in patients with Alport syn-
drome.
The CARDINAL phase 3 trial has enrolled a total of 
157 patients in 16 months, including 134 adult and 23 pe-
diatric patients. The trial studied multiple stages of the 
disease and has included patients with a wide range of 
baseline eGFR (30–90 mL/min/1.73 m2). The mean base-
line age in the trial was 39.2 years, which supports the no-
tion that Alport syndrome generally afflicts a younger pa-
tient population than many other forms of CKD.
Patients with Alport syndrome are usually diagnosed 
due to onset of hematuria in childhood or early adult-
hood, followed later by proteinuria and progressive loss 
of kidney function. Although the severity of disease man-
ifestations differs by the type of causative mutation, all 
forms of Alport syndrome are characterized by progres-
sive nephropathy and are therefore associated with an in-
creased risk for progression to ESKD. In male patients 
with X-linked Alport syndrome, the median age at onset 
of ESKD is 25 years; the incidence of kidney failure in-
creases to 90% by age 40 and nearly 100% by age 60 for 
these patients [26]. Alport syndrome accounts for an es-
timated 0.2% of adults and 3% of children with ESKD in 
the USA [3]. As a result, children and young adults diag-
nosed with Alport syndrome may experience a dramatic 
increase in the risk of cardiovascular and other adverse 
health events and altered growth.
As is the case with other chronic progressive kidney 
diseases, inflammation has been shown to be a pathogen-
ic feature of Alport syndrome that correlates with declin-
ing kidney function [27]. Data from multiple animal 
models of CKD demonstrate that bardoxolone methyl 
and closely related structural analogs suppress inflamma-
tion and fibrosis, reduce glomerulosclerosis, prevent tu-
bulointerstitial damage, and improve kidney function 
[20–24]. Additional studies have demonstrated that acute 
treatment with bardoxolone methyl reverses endothelial 
dysfunction and mesangial cell contraction, increases 
glomerular surface area (Kf), and restores single nephron 
glomerular filtration rate without changes in intraglo-
merular pressure [28, 29]. Because of these properties, 
bardoxolone methyl may be effective at ameliorating the 
rate of decline in eGFR in patients with Alport syndrome.
A prior trial (BEACON, NCT01351675) showed that 
patients with type 2 diabetes mellitus and stage 4 CKD 
randomized to bardoxolone methyl experienced a signif-
icant increase in events of heart failure or fluid overload; 
the excess risk was evident during the first 4 weeks of the 
trial. In post hoc analyses, patients with a history of heart 
failure or an elevated BNP (>200 ng/mL) were found to 
be at increased risk [17, 30]. As a result, subsequent clin-
ical trials, including CARDINAL, excluded patients with 
those clinical characteristics as well as severe (stage 4) 
CKD and UACR >3,500 mg/g. Additionally, unlike BEA-
CON, CARDINAL utilized a dose-titration regimen to 
allow for individual dose optimization based on tolerabil-
ity and to potentially mitigate some of the tolerability is-
sues thought to be related to fixed dosing in BEACON. 
The maximum allowable dose was determined based on 
a patient’s albuminuria status at baseline. Results from a 
prior dose-ranging trial in patients with diabetic kidney 
disease suggested that higher bardoxolone methyl doses 
may be required to have an optimal effect on eGFR in pa-
tients with macroalbuminuria. Specifically, in patients 
with macroalbuminuria at baseline, a 30-mg dose was re-
quired to produce an eGFR response that was similar to 
that in patients with microalbuminuria treated at 20 mg. 
Consequently, CARDINAL included dose titration up to 
a maximum dose of 20 mg (same dose as that utilized in 
BEACON) for patients with UACR ≤300 mg/g and a 
maximum dose of 30 mg for patients with UACR >300 
mg/g. The trial also limited enrollment of patients with 
baseline UACR >300 mg/g to approximately 40% of the 
randomized population, which may have excluded some 
patients at highest risk for progression from entering the 
trial. Nevertheless, despite the majority of patients having 
baseline UACR ≤300 mg/g, approximately 40% of ran-
domized patients had baseline eGFR ≤60 mL/min/1.73 
m2, demonstrating progressive loss of kidney function 
even in patients with lower levels of albuminuria and de-
spite the use of ACEi or ARB therapy in more than three-
quarters of trial participants. Moreover, the average rate 
of annual eGFR decline prior to enrollment in the study 
was −4.9 mL/min/1.73 m2, consistent with that observed 
in a prior Alport syndrome natural history study (−4.0 
mL/min/1.73 m2; [31]), and more pronounced than that 
reported in other forms of CKD, including diabetic kid-
ney disease, hypertensive CKD, and ADPKD [32–34]. 
Additional evaluation of the trial population by baseline 
eGFR or UACR categories showed that patients with Al-
port syndrome with more advanced kidney disease (ei-
ther lower eGFR or higher UACR) tended to have X-
linked Alport syndrome, were receiving ACEi or ARB, 
and exhibited other manifestations of the disease, includ-
ing hearing loss.
While the majority of adult patients randomized into 
the trial were female, all but four of the pediatric patients 
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were male. The predominance of male sex in the pediatric 
population is likely due to the fact that a majority of the 
patients enrolled in the study had an X-linked mode of in-
heritance, and X-linked male patients typically develop 
symptoms of Alport syndrome earlier than female patient 
[35]. Data from CARDINAL phase 3 demonstrate a more 
severe course of kidney disease in pediatric patients with 
Alport syndrome, who were predominantly male patients 
with X-linked genetic defects; their mean baseline UACR 
was higher, and despite their younger age, their mean base-
line eGFR was similar to that of the adult population. Last-
ly, pediatric patients had an average annual eGFR decrease 
of −10.7 mL/min/1.73 m2 prior to enrollment in the trial.
Overall, the demographic and baseline characteristics 
of patients enrolled in the CARDINAL trial are represen-
tative of the Alport syndrome patient population and are 
generally consistent with the characteristics of patients 
enrolled in a prior natural history study in Alport syn-
drome (ATHENA; [31]). Notable differences included 
the distribution of male versus female patients; while 
more than one-half of patients randomized in CARDI-
NAL were female, they comprised over two-thirds of the 
total enrolled population in ATHENA.
In CARDINAL, the diagnosis of Alport syndrome was 
confirmed either histologically or through genetic test-
ing. More specifically, patients with a documented muta-
tion in genes associated with Alport syndrome, including 
COL4A3, COL4A4, or COL4A5, were enrolled in the trial. 
Approximately 62% of randomized patients had X-linked 
Alport syndrome, with COL4A5 mutations. Because fam-
ily history data were not collected as part of the study, we 
were unable to distinguish between autosomal dominant 
or autosomal recessive forms of the disease based on ge-
netic testing alone. Nevertheless, the criteria used to de-
fine genetic confirmation of Alport syndrome are consis-
tent with recent recommendations from the Alport Syn-
drome Classification Working Group. Notably, the 
Working Group proposed unifying the classification of 
all genetic disorders arising from COL4A mutations as an 
Alport Syndrome spectrum [4]. Accordingly, other 
known collagen-related kidney diseases, such as thin 
basement membrane nephropathy, benign familial he-
maturia, familial proteinuria, and some forms of FSGS, 
may also be classified as Alport syndrome under the pro-
posed classification scheme. Furthermore, adopting this 
new classification system may also suggest that there are 
more patients with Alport syndrome who are undiag-
nosed or misdiagnosed [36].
The newly proposed classification scheme is based on 
genetic criteria instead of relying solely on histologic and 
clinical traits that are sex- and age-dependent and under-
scores the need for genetic testing in chronic kidney dis-
eases. Indeed, recent expert consensus guidelines recom-
mend genetic testing, which is more sensitive and spe-
cific than kidney biopsy, as the gold standard for the 
confirmation of an Alport syndrome diagnosis [37]. This 
idea has been supported by several recent studies that 
demonstrated significant diagnostic capabilities of genet-
ic testing in patients with a variety of chronic kidney dis-
eases. For example, genetic testing was shown to provide 
an accurate diagnosis in up to 40% of patients with kidney 
disease of unknown etiology [38]. Separately, recent gene 
sequencing studies have consistently demonstrated that 
variants in COL4A3, COL4A4, and COL4A5 commonly 
result in sporadic and familial adult FSGS, which should 
be identified as Alport syndrome based on the reclassifi-
cation proposal [39, 40]. Likewise, Groopman et al. [41] 
demonstrated that almost 10% of patients with kidney 
disease tested by whole exome sequencing had a genetic 
defect, with COL4A gene variants being most common. 
In patients with suspected Alport syndrome, high 
throughput-targeted next-generation sequencing tech-
nologies with a customized panel for testing all 3 Alport 
genes – COL4A3, COL4A4, and COL4A5 – together can 
identify up to 95% of pathogenic COL4A variants [7, 37].
In conclusion, CARDINAL is the largest intervention-
al, randomized controlled study in Alport syndrome that 
uniquely offers insights into the characteristics of an Al-
port syndrome trial population. Despite the frequent use 
of ACEi or ARB therapy, the CARDINAL trial population 
still exhibited varying degrees of compromised kidney 
function at baseline, with meaningful historical rates of 
kidney function loss. These findings emphasize the need 
for novel therapeutic agents in this population and ren-
ders CARDINAL results relevant to the broader popula-
tion of patients with Alport syndrome.
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